Catalent (NYSE:CTLT) Posts Earnings Results, Misses Expectations By $0.18 EPS

Catalent (NYSE:CTLT) announced its earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18), Briefing.com reports. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.10) earnings per share.

Catalent Trading Down 0.4 %

CTLT stock traded down $0.24 during trading on Friday, hitting $59.68. The company had a trading volume of 346,159 shares, compared to its average volume of 2,041,880. Catalent has a 52-week low of $32.38 and a 52-week high of $61.20. The company has a 50 day simple moving average of $60.01 and a 200-day simple moving average of $58.05. The firm has a market capitalization of $10.83 billion, a P/E ratio of -10.91, a PEG ratio of 2.06 and a beta of 1.16. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35.

Wall Street Analyst Weigh In

CTLT has been the topic of a number of recent research reports. Robert W. Baird restated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research report on Thursday, July 11th. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, StockNews.com cut shares of Catalent from a “hold” rating to a “sell” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and eight have assigned a hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $59.83.

Insider Buying and Selling at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.31% of the stock is owned by corporate insiders.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.